[caption id="attachment_9277" align="aligncenter" width="1079"] Press Release[/caption]

Lynparza reduced the risk of disease progression or death by 47% in patients whose disease had not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen

Only PARP inhibitor approved in germline BRCA-mutated metastatic pancreatic cancer.

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that?Lynparza?(olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease has not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen. Patients will be selected for therapy based on an FDA-approved companion diagnostic for?Lynparza. The approval follows the?recommendation?from the US FDA Oncologic Drugs Advisory Committee (ODAC) on 17 December for?Lynparza?in this indication, and was based on results from the pivotal?Phase III POLO trial?published in?The New England Journal of Medicine?and presented at the 2019 American Society of Clinical Oncology Annual Meeting. Results showed a statistically significant and clinically meaningful improvement in progression-free survival, where?Lynparza?nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months vs. 3.8 months on placebo. The safety and tolerability profile of?Lynparza?in the POLO trial was in line with that observed in prior clinical trials. Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: ?Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades.?Lynparza?is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer.? Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: ?Lynparza?embodies MSD?s and AstraZeneca?s commitment to advance the treatment of challenging types of cancer, including metastatic pancreatic cancer. The expanded approval of?Lynparza?represents a significant milestone for patients and supports the value of germline BRCA testing in patients with this disease.? Hedy L. Kindler, Co-Principal Investigator of the POLO trial and Professor of Medicine, University of Chicago Medicine, said: ?Today?s approval of olaparib based on the POLO results gives clinicians an important 1st-line maintenance treatment option which nearly doubled the progression-free survival benefit in patients with germline BRCA-mutated metastatic pancreatic cancer.? Julie Fleshman, President and CEO, Pancreatic Cancer Action Network, said: ?Metastatic pancreatic cancer patients have been waiting a long time for new therapy options for their devastating disease. Today?s approval of?Lynparza?provides an exciting new treatment option for patients with germline BRCA-mutated metastatic pancreatic cancer.? The?Pancreatic Cancer Action Network?(PanCAN) is a US-based organisation that supports and advocates on behalf of the patients, caregivers and communities affected by pancreatic cancer. About pancreatic cancer Pancreatic cancer is a deadly cancer with a high unmet medical need. It is the 12th most commonly occurring cancer^2?and the 7th leading cause of cancer death globally.³?The disease has the lowest survival rate of the most common cancers^4,5?and is the only major cancer with a single-digit five-year survival rate (2-9%) in nearly every country.⁵?There were approximately 460,000 new cases worldwide in 2018^6.?As there are often no symptoms, or symptoms may be non-specific in the early stages⁷, it is most commonly diagnosed at an incurable stage.^8?Around 80% of pancreatic cancer patients are diagnosed when the disease has metastasised and for these the average survival is less than a year.⁹?Despite advances in treatment¹⁰, few improvements have been made in diagnosis and treatment over the decades.^11,12?Current treatment is surgery (for which approximately only 10-20% of patients are eligible), chemotherapy and radiotherapy, highlighting a critical unmet medical need for more effective treatment options.¹³ About POLO POLO is a Phase III randomised, double-blinded, placebo-controlled, multi-centre trial of?Lynparza?tablets (300mg twice daily) as maintenance monotherapy vs. placebo. The trial randomised 154 patients with gBRCAm metastatic pancreatic cancer whose disease had not progressed on 1st-line platinum-based chemotherapy. Patients were randomised (3:2) to receive?Lynparza?or placebo until disease progression. The primary endpoint was PFS and key secondary endpoints included overall survival, time to second disease progression, overall response rate and health-related quality of life.¹ The results showed a statistically significant and clinically meaningful improvement in progression-free survival, where?Lynparza?nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months vs. 3.8 months on placebo and reduced the risk of disease progression or death by 47% (HR 0.53 [95% CI, 0.35-0.81], p=0.0035). The benefit of maintenance with?Lynparza?was seen consistently across a range of clinically meaningful endpoints. In patients with measurable disease at baseline, 23% responded to?Lynparza?vs.12% on placebo (odds ratio, 2.30; 95% CI, 0.89 to 6.76) and had a median duration of treatment in excess of two years (24.9 months; 95% CI, 14.8 to could not be calculated) vs 3.7 months on placebo (95% CI, 2.1 to could not be calculated). Overall survival (OS), a secondary endpoint, at interim analysis was 18.9 months for?Lynparza?vs. 18.1 months for placebo but did not reach statistical significance (HR=0.90; p=0.68). The safety and tolerability profile of?Lynparza?in the POLO trial was in line with that observed in prior clinical trials. The most common adverse reactions (ARs) =10% were fatigue (60%), nausea (45%), abdominal pain (34%), diarrhoea (29%), anaemia (27%), decreased appetite (25%), constipation (23%), vomiting (20%), back pain (19%), arthralgia (15%), rash (15%), thrombocytopenia (14%), dyspnoea (13%), nasopharyngitis (12%), neutropenia (12%), dysgeusia (11%) and stomatitis (10%). Grade 3 or above ARs were anaemia (11%), fatigue (5%), neutropenia (4%), decreased appetite (3%), thrombocytopenia (3%), abdominal pain (2%), vomiting (1%) and arthralgia (1%). ARs led to dose reduction in 23% of patients on?Lynparza?while 6% of patients discontinued treatment. Based on the results of POLO, the National Comprehensive Cancer Network (NCCN) guidelines were updated in July 2019 to recommend?Lynparza?as maintenance treatment for gBRCAm pancreatic cancer.¹⁴ In the US, eligible metastatic pancreatic cancer patients will be selected for therapy based on the FDA-approved companion diagnostic, BRACAnalysis CDx, a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. BRACAnalysis CDx is owned and commercialised by Myriad Genetics, Inc. About BRCA mutations BRCA1 and BRCA2 (breast cancer susceptibility genes 1/2) are human genes that produce proteins responsible for repairing damaged DNA and play an important role in maintaining the genetic stability of cells. When either of these genes is mutated, or altered, such that its protein product either is not made or does not function correctly, DNA damage may not be repaired properly, and cells become unstable. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer. About?Lynparza Lynparza?(olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2. Inhibition of PARP with?Lynparza?leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.?Lynparza?is being tested in a range of PARP-dependent tumour types with defects and dependencies in the DDR pathway. Lynparza?is currently approved in 65 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. It is approved in the US, the EU, Japan, China and several other countries as 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy. It is also approved in 44 countries, including the US and Japan, for germline BRCA-mutated, HER2-negative, metastatic breast cancer, previously treated with chemotherapy; in the EU, this includes locally advanced breast cancer. Regulatory reviews are underway in other jurisdictions for ovarian, breast and pancreatic cancers. Lynparza, which is being jointly developed and commercialised by AstraZeneca and MSD, is approved for advanced ovarian cancer and metastatic breast cancer and has been used in over 25,000 patients worldwide.?Lynparza?has the broadest and most advanced clinical trial development programme of any PARP inhibitor, and AstraZeneca and MSD are working together to understand how it may affect multiple PARP-dependent tumours as a monotherapy and in combination across multiple cancer types.?Lynparza?is the foundation of AstraZeneca?s industry-leading portfolio of potential new medicines targeting DDR mechanisms in cancer cells. About the AstraZeneca and MSD strategic oncology collaboration In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the United States and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialise?Lynparza, the world?s first PARP inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. Working together, the companies will develop?Lynparza?and selumetinib in combination with other potential new medicines and as monotherapies. Independently, the companies will develop?Lynparza?and selumetinib in combination with their respective PD-L1 and PD-1 medicines. About AstraZeneca in oncology AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients? lives and the Company?s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to AstraZeneca?s main capabilities, the Company is actively pursuing innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by the investment in Acerta Pharma in haematology. By harnessing the power of four scientific platforms ? Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates ? and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death. About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit?astrazeneca.com?and follow the Company on Twitter?@AstraZeneca.